A PROSPECTIVE STUDY INVOLVING COMPARISON OF ACOTIAMIDE WITH RABEPRAZOLE VS. DOUBLE DOSE RABEPRAZOLE IN PATIENTS HAVING OVERLAPPING SYMPTOMS OF PROTON PUMP INHIBITOR REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPEPSIA
DOI:
https://doi.org/10.29121/granthaalayah.v8.i1.2020.234Keywords:
Functional Dyspepsia (FD), PPI Refractory Gastroesophageal Reflux Disease (GERD), Proton Pump Inhibitor (PPI), Acotiamide, Rabeprazole, Izumo Scale, Frequency Scale for Symptoms of GERD (FSSG Scale)Abstract [English]
Introduction: Gastroesophageal reflux disease (GERD) is a digestive disorder that affects the lower esophageal sphincter (LES). Functional dyspepsia (FD) is characterized by troublesome early satiety, epigastralgia or heart burn. It is often overlooked as the symptoms overlap with GERD. This study aims to compare the effectiveness of Acotiamide+Rabeprazole vs. a double dose of Rabeprazole in Indian population.
Method: In this study 60 patients diagnosed with PPI refractory GERD (taking PPI>8weeks) and FD with no gastric or duodenal organic abnormalities were randomly allocated in two groups. Group 1 received a combination of Acotiamide (200mg/day) +Rabeprazole (20mg/day) and group 2 received a double dose of Rabeprazole (40mg/day). Follow ups were done every month for 3 consecutive months. The frequency and severity of symptoms were assessed using standard Izumo scale and FSSG scale.
Results: The total score and GERD score from the baseline were significantly reduced in group 1 however the reduction in FD score from baseline did not differ significantly in the two treatment groups according to F-scale. The proportion of patients with ≥ 50% reduction in the total score for three upper gastrointestinal symptoms (heart burn, epigastralgia, and epigastric fullness) in the izumo scale was 96.7% in group 1 and 33.3% in group 2. Significant difference were noticed between the two groups. No serious adverse events were observed.
Conclusion: The combination group of Acotiamide+Rabeprazole was found to be more effective than double dose of Rabeprazole in reducing the overlapping symptoms of PPI refractory GERD and FD.
Downloads
References
The Changing Epidemiology of Gastroesophageal Reflux Disease: Are Patients Getting Younger? Takahisa Yamasaki,1 Colin Hemond,2 Mohamed Eisa,3 Stephen Ganocy,4 and Ronnie Fass1,*- J Neurogastroenterol Motil. 2018 Oct; 24(4): 559–569. DOI: https://doi.org/10.5056/jnm18140
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006; 101: 1900–20.
Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999; 72(2-3): 93-100.
Pharmacotherapeutics by Joseph. T. Dipiro- 9th Edition.
Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions Joseph Mermelstein,1 Alanna Chait Mermelstein,2 and Maxwell M Chait3 - Clin Exp Gastroenterol. 2018; 11: 119–134. DOI: https://doi.org/10.2147/CEG.S121056
Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions-Joseph Mermelstein, Alanna Chait Mermelstein, and Maxwell M Chait- Clin Exp Gastroenterol. 2018; 11: 119–134. DOI: https://doi.org/10.2147/CEG.S121056
New classification Rome IV functional dyspepsia and subtypes Seiji Futagami, Hiroshi Yamawaki, Shuhei Agawa, Kazutoshi Higuchi, Go Ikeda, Hiroto Noda, Kumiko Kirita, Teppei Akimoto, Mako Wakabayashi, Noriko Sakasegawa, Yasuhiro Kodaka, Nobue Ueki, Tetsuro Kawagoe, Katsuhiko Iwakiri- Transl Gastroenterol Hepatol 2018;3:70 DOI: https://doi.org/10.21037/tgh.2018.09.12
Toshihisa Takeuchi, Yoshiaki Takahashi, Shinpei Kawaguchi, Kazuhiro Ota, Satoshi Harada, Yuichi Kojima, Hiroki Sakamoto, Takanori Kuramoto, Keishi Kojima, Makoto Sanomura, Masahiro Hoshimoto, Takeshi Higashino, Tsukasa Itabashi, Ko Takada, Masahiro Sakaguchi, Kazunari Tominaga, Motoyasu Kusano, Kazuhide Higuchi: Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual‐dose proton pump pump inhibitor versus double‐dose proton pump inhibitor- Journal of Gastroenterology and Hepatology-Volume 33, Issue 3, 2017. DOI: https://doi.org/10.1111/jgh.13970
Varsha Narayanan, Shailesh Pallewar, Maneesha Khalse, Amit Bhargava: Real World Efficacy and Tolerability of Acotiamide in Relieving Multiple and Overlapping Symptoms in Patients of Functional Dyspepsia-Archives of Gastroenterology and Hepatology -Volume 1, Issue 1, 2018. DOI: https://doi.org/10.4172/2161-069X.1000553
Development and verification of the Izumo Scale, new questionnaire for quality of life assessment of patients with gastrointestinal symptoms-Furuta K,Ishihara S,Sato S,Miyake T, Ishimura N, Koshino K, Tobita H, Moriyama I, Amano Y, Adachi K, Ohta A, Kinoshita Y- Nihon Shokakbiyo Gakkai Zasshi -2009 Oct;106(10) 1478-87.
New Medical Approach to Functional dyspepsia, from Core Symposium 3, Japan Gastroenterological Association 2015-2017-Hidekazu Suzuki- Digestion- 2018,97,6-12. DOI: https://doi.org/10.1159/000484029
Adherence to an Acotiamide Therapeutic Regimen Improves long term outcomes in patients with Functional dyspepsia- Satoshi Shinozaki, Hiroyuki Osawa, Hirotsugu Sakamoto, Yoshikazu Hayashi, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto- Journal of Gastrointestinal and Liver diseases-Volume 26, 2017. DOI: https://doi.org/10.15403/jgld.2014.1121.264.ski
Downloads
Published
How to Cite
Issue
Section
License
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
